Ovarian Cancer Drugs Market
Ovarian Cancer Drugs Market Research and Analysis, 2015-2022 Update Available - Forecast 2024-2030
The Global ovarian cancer drugs market is expected to grow at a CAGR of 14.09% during 2017-2022. Ovarian cancer is one of the most dangerous cancers among all different cancers in females. This cancer grows inside an ovary, results in abnormal growth of cells that have the tendency to attack or harmfully affect the other parts of the body. Ovarian cancer is difficult to predict since very few vague symptoms show up in the early stages. When the cancer grows considerably it starts to show symptoms which includes abdominal puffiness, inflating, pelvic ache, and loss of appetite. This cancer can spread in the different parts of the body associated with ovary such as liver, lymph nodes, abdomen layers, lining of the bowel and bladder. This diseases is very rare in nature, however, the risk in such kind of cancer is relatively higher. Around 10% of ovarian cancer cases are related to inherited genetic risk. Moreover, there are an estimated 50% chances of development of these diseases to women with mutations in the breast cancer genes.
The most common ovarian cancer is ovarian carcinoma.The market is boosted by the increasing incidence of ovarian cancer, rising aged women population. The need for more effective treatment options is pushing growth of the global ovarian cancer drugs market. High cost of ovarian cancer drugs and inaccurate diagnostic of ovarian cancer acts as a barrier in the growth of this market. The report includes detailed Market Overview, Analyst Insights and predictive analysis, Market Determinants, Market Segmentation, Geographical Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Market Insights and Company Profiling.
Geographical insights
Geographically market is divided into North America, Europe, Asia Pacific and Rest of the World. North America is having the largest market share in this market. U.S and Canada are the two major countries in this region. The major factors that thrives this market are increasing number of aging population, presence of major market players, and adoption of latest technologies. Asia pacific region is expected to show high growth rates in the upcoming years in the ovarian cancer drugs market globally. China and India are anticipated to be the fastest growing ovarian cancer drug markets in Asia Pacific region. Some of the key boosting forces for ovarian cancer drug market in emerging countries arelarge pool of patients, rise in healthcare expenditure, and rising government funding.
Competitive insights
The key players in the global ovarian cancer drugs market includes Roche, BoehringerIngelheim, Amgen, Astrazeneca, Glaxosmithkline, Abraxane, Doxil, Exelixis, Delmar Pharmaceuticals Inc, Bristol-Myers Squibb, Celgene, Alkeran, Lynparza, Novartis Pharmaceuticals Corp, Clovis Oncology, Alza, Eli Lilly And Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc. and so forth. Partnership, r&d, m&a, product launch are the key strategy adopted in the global corrosion inhibitor market.
Market segmentation
GlobalOvarian Cancer Drugs Marketis segmented on the basis ofcancer
type, treatment, drugs and regional outlook. In cancer type segment the
major cancer type is primary peritoneal carcinoma. This is the most
common ovarian cancer type.
1. Global Ovarian Cancer Drugs Market Research And Analysis, By Cancer Type
1.1. Epithelial Ovarian Tumors
1.2. Ovarian Germ Cell Tumors
1.3. Ovarian Stromal Tumors
1.4. Primary Peritoneal Carcinoma
2. Global Ovarian Cancer Drugs Market Research And Analysis, By Treatment
2.1. Chemotherapy
2.1.1. Localized Ovarian Cancer Therapeutics
2.1.2. Metastatic Ovarian Cancer Therapeutics
2.1.3. Recurrent Ovarian Cancer Therapeutics
2.2. Immunotherapy
2.3. Hormonal Therapy
2.4. Targeted Therapy
2.5. Radiation Therapy
2.6. Surgery
3. Global Ovarian Cancer Drugs Market Research And Analysis, By Drugs
3.1. Alkeran (Melphalan)
3.2. Avastin (Bevacizumab)
3.3. Bevacizumab
3.4. Carboplatin
3.5. Clafen (Cyclophosphamide)
3.6. Cisplatin
3.7. Cyclophosphamide
3.8. Cytoxan (Cyclophosphamide)
3.9. Doxorubicin Hydrochloride
3.10. Dox-Sl (Doxorubicin Hydrochloride Liposome)
3.11. Doxil (Doxorubicin Hydrochloride Liposome)
3.12. Doxorubicin Hydrochloride Liposome
3.13. Evacet (Doxorubicin Hydrochloride Liposome)
3.14. Gemcitabine Hydrochloride
4. GlobalGlobal Ovarian Cancer Drugs Market Research And Analysis, By Region
4.1. North America
4.2. Europe
4.3. APAC
4.4. RoW
OMR Report covers
• Comprehensive research methodology of global ovarian cancer drugs market.
• This report also includes detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global ovarian cancer drugs market.
• Insights about market determinants which are stimulating the global ovarian cancer drugs market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2.4. EXCEPTIONS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. RAW MATERIAL ANALYSIS
2.4. REGULATION
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH INCREASE IN HEALTHCARE EXPENDITURE
3.1.2. INCREASING HEALTHCARE AWARENESS
3.1.3. INCREASING INCIDENCES OF OVARIAN CANCER WORLDWIDE
3.1.4. GREATER USE OF COMBINATION THERAPIES FOR THE TREATMENT
3.2. RESTRAINT
3.2.1. LACK OF ACCURATE DIAGNOSIS OF OVARIAN CANCER
3.2.2. LAUNCH OF GENERIC DRUGS
3.3. OPPORTUNITY
3.3.1. RISING POPULATION OF FEMALES IN ASIA PACIFIC REGION
3.3.2. TECHNOLOGICAL ADVANCEMENT IN DRUG SECTOR
4. MARKET SEGMENTATION
4.1. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE
4.1.1. EPITHELIAL OVARIAN TUMOURS
4.1.2. OVARIAN GERM CELL TUMOURS
4.1.3. OVARIAN STROMAL TUMOURS
4.1.4. PRIMARY PERITONEAL CARCINOMA
4.2. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY TREATMENT
4.2.1. CHEMOTHERAPY
4.2.1.1. LOCALIZED OVARIAN CANCER THERAPEUTICS
4.2.1.2. METASTATIC OVARIAN CANCER THERAPEUTICS
4.2.1.3. RECURRENT OVARIAN CANCER THERAPEUTICS
4.2.2. TARGETED THERAPY
4.2.3. RADIATION THERAPY
4.2.4. IMMUNOTHERAPY
4.2.5. HORMONAL THERAPY
4.2.6. SURGERY
4.3. GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUGS
4.4.1. ALKERAN (MELPHALAN)
4.4.2. AVASTIN (BEVACIZUMAB)
4.4.3. BEVACIZUMAB
4.4.4. CARBOPLATIN
4.4.5. CLAFEN (CYCLOPHOSPHAMIDE)
4.4.6. CISPLATIN
4.4.7. CYCLOPHOSPHAMIDE
4.4.8. CYTOXAN (CYCLOPHOSPHAMIDE)
4.4.9. DOXORUBICIN HYDROCHLORIDE
4.4.10. DOX-SL (DOXORUBICIN HYDROCHLORIDE LIPOSOME)
4.4.11. DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME)
4.4.12. DOXORUBICIN HYDROCHLORIDE LIPOSOME
4.4.13. EVACET (DOXORUBICIN HYDROCHLORIDE LIPOSOME)
4.4.14. GEMCITABINE HYDROCHLORIDE
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABRAXANE
7.1.1. INTRODUCTION
7.1.2. ABRAXANE PRODUCT PORTFOLIO
7.1.3. ABRAXANE RECENT ACTIVITIES
7.2. ALKERAN
7.2.1. INTRODUCTION
7.2.2. ALKERAN PRODUCT PORTFOLIO
7.2.3. ALKERAN RECENT ACTIVITIES
7.3. ALZA
7.3.1. INTRODUCTION
7.3.2. ALZA PRODUCT PORTFOLIO
7.3.3. ALZA RECENT ACTIVITIES
7.4. AMGEN
7.4.1. INTRODUCTION
7.4.2. AMGEN PRODUCT PORTFOLIO
7.4.3. AMGEN RECENT ACTIVITIES
7.5. ASTRAZENECA
7.5.1. INTRODUCTION
7.5.2. ASTRAZENECA PRODUCT PORTFOLIO
7.5.3. ASTRAZENECA RECENT ACTIVITIES
7.6. BOEHRINGER INGELHEIM
7.6.1. INTRODUCTION
7.6.2. BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
7.6.3. BOEHRINGER INGELHEIM RECENT ACTIVITIES
7.7. BRISTOL-MYERS SQUIBB
7.7.1. INTRODUCTION
7.7.2. BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
7.7.3. BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
7.8. CELGENE
7.8.1. INTRODUCTION
7.8.2. CELGENE PRODUCT PORTFOLIO
7.8.3. CELGENE RECENT ACTIVITIES
7.9. CLOVIS ONCOLOGY
7.9.1. INTRODUCTION
7.9.2. CLOVIS ONCOLOGY PRODUCT PORTFOLIO
7.9.3. CLOVIS ONCOLOGY RECENT ACTIVITIES
7.10. DELMAR PHARMACEUTICALS INC
7.10.1. INTRODUCTION
7.10.2. DELMAR PHARMACEUTICALS INC PRODUCT PORTFOLIO
7.10.3. DELMAR PHARMACEUTICALS INC RECENT ACTIVITIES
7.11. DOXIL
7.11.1. INTRODUCTION
7.11.2. DOXIL PRODUCT PORTFOLIO
7.11.3. DOXIL RECENT ACTIVITIES
7.12. ELI LILLY AND COMPANY
7.12.1. INTRODUCTION
7.12.2. ELI LILLY AND COMPANY PRODUCT PORTFOLIO
7.12.3. ELI LILLY AND COMPANY RECENT ACTIVITIES
7.13. EXELIXIS
7.13.1. INTRODUCTION
7.13.2. EXELIXIS PRODUCT PORTFOLIO
7.13.3. EXELIXIS RECENT ACTIVITIES
7.14. GENENTECH INC.
7.14.1. INTRODUCTION
7.14.2. GENENTECH INC. PRODUCT PORTFOLIO
7.14.3. GENENTECH INC. RECENT ACTIVITIES
7.15. GLAXOSMITHKLINE
7.15.1. INTRODUCTION
7.15.2. GLAXOSMITHKLINE PRODUCT PORTFOLIO
7.15.3. GLAXOSMITHKLINE RECENT ACTIVITIES
7.16. JANSSEN PHARMACEUTICALS, INC.
7.16.1. INTRODUCTION
7.16.2. JANSSEN PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
7.16.3. JANSSEN PHARMACEUTICALS, INC. RECENT ACTIVITIES
7.17. LYNPARZA
7.17.1. INTRODUCTION
7.17.2. LYNPARZA PRODUCT PORTFOLIO
7.17.3. LYNPARZA RECENT ACTIVITIES
7.18. NOVARTIS PHARMACEUTICALS CORP
7.18.1. INTRODUCTION
7.18.2. NOVARTIS PHARMACEUTICALS CORP PRODUCT PORTFOLIO
7.18.3. NOVARTIS PHARMACEUTICALS CORP RECENT ACTIVITIES
7.19. NOVOGEN, INC.
7.19.1. INTRODUCTION
7.19.2. NOVOGEN, INC. PRODUCT PORTFOLIO
7.19.3. NOVOGEN, INC. RECENT ACTIVITIES
7.20. ROCHE
7.20.1. INTRODUCTION
7.20.2. ROCHE PRODUCT PORTFOLIO
7.20.3. ROCHE RECENT ACTIVITIES
TABLE # 1 GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE 2015-2022 ($MILLION)
TABLE # 2 EPITHELIAL OVARIAN TUMOURS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 3 OVARIAN GERM CELL TUMOURS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 4 OVARIAN STROMAL TUMOURS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 5 PRIMARY PERITONEAL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 6 GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2015-2022 ($MILLION)
TABLE # 7 CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 8 LOCALIZED OVARIAN CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 9 METASTATIC OVARIAN CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 10 RECURRENT OVARIAN CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 11 TARGETED THERAPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 12 RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 13 IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 14 HORMONAL THERAPY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 15 SURGERY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 16 GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY DRUGS 2015-2022 ($MILLION)
TABLE # 17 INSTRUMENTS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 18 SERVICES AND SOFTWARES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 19 REAGENTS MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 20 GLOBAL OVARIAN CANCER DRUGS MARKET RESEARCH AND ANALYSIS, BY END USERS
TABLE # 21 ALKERAN (MELPHALAN) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 22 AVASTIN (BEVACIZUMAB) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 23 BEVACIZUMAB MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 24 CARBOPLATIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 25 CLAFEN (CYCLOPHOSPHAMIDE) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 26 CISPLATIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 27 CYCLOPHOSPHAMIDE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 28 CYTOXAN (CYCLOPHOSPHAMIDE) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 29 DOXORUBICIN HYDROCHLORIDE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 30 DOX-SL (DOXORUBICIN HYDROCHLORIDE LIPOSOME) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 31 DOXIL (DOXORUBICIN HYDROCHLORIDE LIPOSOME) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 32 DOXORUBICIN HYDROCHLORIDE LIPOSOME MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 33 EVACET (DOXORUBICIN HYDROCHLORIDE LIPOSOME) MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 34 GEMCITABINE HYDROCHLORIDE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
TABLE # 35 ABRAXANE PRODUCT PORTFOLIO
TABLE # 36 ABRAXANE RECENT ACTIVITIES
TABLE # 37 ALKERAN PRODUCT PORTFOLIO
TABLE # 38 ALKERAN RECENT ACTIVITIES
TABLE # 39 ALZA PRODUCT PORTFOLIO
TABLE # 40 ALZA RECENT ACTIVITIES
TABLE # 41 AMGEN PRODUCT PORTFOLIO
TABLE # 42 AMGEN RECENT ACTIVITIES
TABLE # 43 ASTRAZENECA PRODUCT PORTFOLIO
TABLE # 44 ASTRAZENECA RECENT ACTIVITIES
TABLE # 45 BOEHRINGER INGELHEIM PRODUCT PORTFOLIO
TABLE # 46 BOEHRINGER INGELHEIM RECENT ACTIVITIES
TABLE # 47 BRISTOL-MYERS SQUIBB PRODUCT PORTFOLIO
TABLE # 48 BRISTOL-MYERS SQUIBB RECENT ACTIVITIES
TABLE # 49 CELGENE PRODUCT PORTFOLIO
TABLE # 50 CELGENE RECENT ACTIVITIES
TABLE # 51 CLOVIS ONCOLOGY PRODUCT PORTFOLIO
TABLE # 52 CLOVIS ONCOLOGY RECENT ACTIVITIES
TABLE # 53 DELMAR PHARMACEUTICALS INC PRODUCT PORTFOLIO
TABLE # 54 DELMAR PHARMACEUTICALS INC RECENT ACTIVITIES
TABLE # 55 DOXIL PRODUCT PORTFOLIO
TABLE # 56 DOXIL RECENT ACTIVITIES
TABLE # 57 ELI LILLY AND COMPANY PRODUCT PORTFOLIO
TABLE # 58 ELI LILLY AND COMPANY RECENT ACTIVITIES
TABLE # 59 EXELIXIS PRODUCT PORTFOLIO
TABLE # 60 EXELIXIS RECENT ACTIVITIES
TABLE # 61 GENENTECH INC. PRODUCT PORTFOLIO
TABLE # 62 GENENTECH INC. RECENT ACTIVITIES
TABLE # 63 GLAXOSMITHKLINE PRODUCT PORTFOLIO
TABLE # 64 GLAXOSMITHKLINE RECENT ACTIVITIES
TABLE # 65 JANSSEN PHARMACEUTICALS, INC. PRODUCT PORTFOLIO
TABLE # 66 JANSSEN PHARMACEUTICALS, INC. RECENT ACTIVITIES
TABLE # 67 LYNPARZA PRODUCT PORTFOLIO
TABLE # 68 LYNPARZA RECENT ACTIVITIES
TABLE # 69 NOVARTIS PHARMACEUTICALS CORP PRODUCT PORTFOLIO
TABLE # 70 NOVARTIS PHARMACEUTICALS CORP RECENT ACTIVITIES
TABLE # 71 NOVOGEN, INC. PRODUCT PORTFOLIO
TABLE # 72 NOVOGEN, INC. RECENT ACTIVITIES
TABLE # 73 ROCHE PRODUCT PORTFOLIO
TABLE # 74 ROCHE RECENT ACTIVITIES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 6 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 7 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 8 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 9 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 15 ROPAC MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
FIGURE # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022 ($MILLION)
